Gain Therapeutics - Unfolding the next generation of allosteric small molecule therapies to meet patient needs
- Details
- Written by: web web
- Category: Home
- Hits: 3741
Gain’s lead drug candidate is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. is currently being evaluated in a Phase I clinical study.
Lead Program >>
- Details
- Written by: web web
- Category: Home
- Hits: 4321
By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Our Platform >>
- Details
- Written by: web web
- Category: Home
- Hits: 3891
ALLOSTERIC PROTEIN REGULATION
Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.
Our Science >>
- Details
- Written by: web web
- Category: Home
- Hits: 4521
October 2024
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Ther...
BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”,...